September 16, 2020 — More than 200 people joined to file a Zantac class-action lawsuit in the U.S. District Court for the Southern District of Florida. The plaintiffs brought the action on behalf of themselves and all other similarly situated residents of the U.S. or its territories who purchased and/or used Zantac for personal use.
According to the complaint, Zantac manufacturers deceived millions of consumers into “purchasing and ingesting a defective, misbranded, adulterated, and harmful drug” while failing to warn about the potential for that drug to conatin N-nitrosodimethylamine (NDMA), a cancer-causing agent.
The plaintiffs claim they would never have used the medication if they were aware of its potential to contain NDMA. They say that the defendants knew or should have known of the NDMA risk in their products as early studies showed the possibility of conversion into cancerous N-nitroso compounds.
Additionally, the plaintiffs state that the defendants long knew that NDMA could be formed, yet failed to take any action to protect consumers.
Reference: Luhana, R. (2020, September 15). New Class Action Zantac Lawsuit Includes Claims from Over 200 Zantac Users. Retrieved September 23, 2020, www.newyork.legalexaminer.com/legal/new-class-action-zantac-lawsuit-includes-claims-from-over-200-zantac-users/